Zymeworks Capital Lease Obligations from 2010 to 2025
| ZYME Stock | USD 12.37 0.14 1.12% |
Capital Lease Obligations | First Reported 2019-03-31 | Previous Quarter 20.2 M | Current Value 18.5 M | Quarterly Volatility 10.7 M |
Check Zymeworks Common financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Zymeworks Common's main balance sheet or income statement drivers, such as Interest Expense of 5.8 M, Selling General Administrative of 64.6 B or Total Revenue of 78.7 M, as well as many indicators such as Price To Sales Ratio of 13.82, Dividend Yield of 0.0 or PTB Ratio of 0.0031. Zymeworks financial statements analysis is a perfect complement when working with Zymeworks Common Valuation or Volatility modules.
Zymeworks | Capital Lease Obligations |
Latest Zymeworks Common's Capital Lease Obligations Growth Pattern
Below is the plot of the Capital Lease Obligations of Zymeworks Common Stock over the last few years. Zymeworks Common Stock capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Zymeworks Common asset purchases. For example, Zymeworks Common can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Zymeworks Common control over an asset for a big portion of its life. It is the total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee. Zymeworks Common's Capital Lease Obligations historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Zymeworks Common's overall financial position and show how it may be relating to other accounts over time.
| Capital Lease Obligations | 10 Years Trend |
|
Capital Lease Obligations |
| Timeline |
Zymeworks Capital Lease Obligations Regression Statistics
| Arithmetic Mean | 9,139,588 | |
| Geometric Mean | 298,856 | |
| Coefficient Of Variation | 143.66 | |
| Mean Deviation | 10,598,683 | |
| Median | 62,000 | |
| Standard Deviation | 13,130,315 | |
| Sample Variance | 172.4T | |
| Range | 41.2M | |
| R-Value | 0.74 | |
| Mean Square Error | 84.9T | |
| R-Squared | 0.54 | |
| Significance | 0 | |
| Slope | 2,027,093 | |
| Total Sum of Squares | 2586.1T |
Zymeworks Capital Lease Obligations History
About Zymeworks Common Financial Statements
Zymeworks Common stakeholders use historical fundamental indicators, such as Zymeworks Common's Capital Lease Obligations, to determine how well the company is positioned to perform in the future. Although Zymeworks Common investors may analyze each financial statement separately, they are all interrelated. For example, changes in Zymeworks Common's assets and liabilities are reflected in the revenues and expenses on Zymeworks Common's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Zymeworks Common Stock. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Capital Lease Obligations | 18.5 M | 15.9 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out the analysis of Zymeworks Common Correlation against competitors. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zymeworks Common. If investors know Zymeworks will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zymeworks Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.62) | Revenue Per Share | Quarterly Revenue Growth 0.833 | Return On Assets | Return On Equity |
The market value of Zymeworks Common Stock is measured differently than its book value, which is the value of Zymeworks that is recorded on the company's balance sheet. Investors also form their own opinion of Zymeworks Common's value that differs from its market value or its book value, called intrinsic value, which is Zymeworks Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zymeworks Common's market value can be influenced by many factors that don't directly affect Zymeworks Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zymeworks Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zymeworks Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zymeworks Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.